Drug Profile
Research programme: thrombopoietin derivatives - Bolder BioTechnology
Latest Information Update: 22 Mar 2007
Price :
$50
*
At a glance
- Originator Bolder BioTechnology
- Class
- Mechanism of Action Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 22 Mar 2007 Discontinued - Preclinical for Thrombocytopenia in USA (unspecified route)
- 16 Jan 2003 Preclinical trials in Thrombocytopenia in USA (unspecified route)